Persons with screening-detected haemochromatosis: as healthy as the general population?
BACKGROUND
Hereditary haemochromatosis (HH) is a common genetic disease leading to iron deposition in the liver and other organs. Early treatment will prevent clinical disease and population-based screening for HH has been advocated. However, the benefit of screening depends on the morbidity of HH. We have compared the morbidity in HH persons detected by screening with the morbidity in the rest of the population.


METHODS
All inhabitants 20 years or older in a Norwegian county (94,191 persons) were invited to participate in a health survey programme. Of 65,717 participating persons, a blood specimen for transferrin saturation was obtained from 65,238. After repeated laboratory testing and clinical examination, 269 persons were found to have phenotypic HH, while 297 had genotypic HH (the C282/C282Y mutation). Using self-reported data, clinical examinations and analysis of non-fasting blood samples, the morbidity in phenotypic and genotypic HH persons was compared with the morbidity in the rest of the population. All data were collected before subjects were diagnosed with HH, and all comparisons were corrected for age and gender.


RESULTS
Compared to control persons, phenotypic and genotypic HH men and women had a higher score on 1 of 17 questions dealing with joint complaints. Phenotypic and genotypic HH women below 50 years of age had a higher prevalence of hypothyroidism (15.2% and 12.5%, respectively, compared to 3.0% in the control population). Phenotypic HH women below 50 years of age had higher diastolic blood pressure than control women. Phenotypic HH men above 50 years of age and genotypic HH men scored lower than control men on a compound myocardial infarction risk score variable, in part due to lower serum cholesterol concentration. Fewer phenotypic HH men above 50 years of age reported having angina pectoris. Otherwise, the health of phenotypic and genotypic HH persons was not different from the health of control persons.


CONCLUSIONS
When corrected for age and gender, the morbidity in persons with screening-detected HH was not very different from the morbidity in the control group, indicating that population-based screening may not be as beneficial as anticipated.
Asberg
A
A
Dept of Clinical Chemistry, Trondheim University Hospital, Norway. arne.asberg@rit.no
Hveem
K
K
Krüger
O
O
Bjerve
K S
KS
D000328:Adult; D017677:Age Distribution; D000368:Aged; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000453:epidemiology; D015897:Comorbidity; D003920:Diabetes Mellitus / Q000175:diagnosis / Q000453:epidemiology; D005260:Female; D006304:Health Status; D006306:Health Surveys; D006432:Hemochromatosis / Q000175:diagnosis* / Q000453:epidemiology* / Q000235:genetics; D006801:Humans; D007037:Hypothyroidism / Q000175:diagnosis / Q000453:epidemiology; D008107:Liver Diseases / Q000175:diagnosis / Q000453:epidemiology; D016015:Logistic Models; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D009664:Norway / Q000453:epidemiology; D015995:Prevalence; D011336:Probability; D011788:Quality of Life; D012016:Reference Values; D012216:Rheumatic Diseases / Q000175:diagnosis / Q000453:epidemiology; D012720:Severity of Illness Index; D017678:Sex Distribution